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AbstrACt
Objective Individual patients with the same condition 
may respond differently to similar treatments. Our aim is 
to summarise the reporting of person-level heterogeneity 
of treatment effects (HTE) in multiperson N-of-1 studies 
and to examine the evidence for person-level HTE through 
reanalysis.
study design Systematic review and reanalysis of 
multiperson N-of-1 studies.
Data sources Medline, Cochrane Controlled Trials, 
EMBASE, Web of Science and review of references through 
August 2017 for N-of-1 studies published in English.
study selection N-of-1 studies of pharmacological 
interventions with at least two subjects.
Data synthesis Citation screening and data extractions 
were performed in duplicate. We performed statistical 
reanalysis testing for person-level HTE on all studies 
presenting person-level data.
results We identified 62 multiperson N-of-1 studies 
with at least two subjects. Statistical tests examining HTE 
were described in only 13 (21%), of which only two (3%) 
tested person-level HTE. Only 25 studies (40%) provided 
person-level data sufficient to reanalyse person-level HTE. 
Reanalysis using a fixed effect linear model identified 
statistically significant person-level HTE in 8 of the 13 
studies (62%) reporting person-level treatment effects 
and in 8 of the 14 studies (57%) reporting person-level 
outcomes.
Conclusions Our analysis suggests that person-level HTE 
is common and often substantial. Reviewed studies had 
incomplete information on person-level treatment effects 
and their variation. Improved assessment and reporting 
of person-level treatment effects in multiperson N-of-1 
studies are needed.
IntrODuCtIOn 
Clinicians commonly observe that individual 
patients given the same treatment for the 
same condition appear to respond differ-
ently from one another. This observation, 
combined with our understanding of the 
complex mechanisms of diseases and thera-
pies and the potential importance of myriad 
patient-specific factors (eg, age, sex, illness 
severity, comorbidities, co-treatments and 
molecular differences influencing pharma-
cokinetics and dynamics), has led to a widely 
held assumption that the observed variation 
in treatment response seen between individ-
uals is not merely random, but stable and 
potentially predictable. This assumption 
underpins the field of personalised medi-
cine, which aims to determine the best treat-
ment for an individual patient, as opposed 
to treating all patients with the intervention 
found to be most effective for the ‘average’ 
patient.
Nevertheless, statistical analyses aimed 
at discovering heterogeneity of treatment 
effects (HTE) among groups of individ-
uals (eg, subgroup analyses of parallel arm 
randomised trials) typically fail to find 
compelling and reliable evidence for the 
presence of such heterogeneity. For example, 
statistically significant differences in treat-
ment effects between men and women are 
often reported, but a systematic review indi-
cates that the frequency of these interactions 
across studies suggests that the vast majority 
occur by chance.1 Similarly, the field of phar-
macogenetics, also built on the assumption of 
stable variation in treatment responses, has 
strengths and limitations of this study
 ► Our analysis suggests that person-level heterogene-
ity of treatment effects (HTE) is common and often 
substantial.
 ► Our analysis was limited by the paucity of N-of-1 
studies in the literature and by the low statistical 
power in the available studies.
 ► Multiperson N-of-1 studies are the best design to 
estimate individual patient treatment effects and 
compare the variation in effects between individ-
uals to variation within individuals across different 
periods.
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largely failed to live up to its promise to broadly improve 
the targeting of drugs—particularly outside the special 
case of oncology (where studies generally depend on 
the subclassification of tumour tissue not on variation in 
germ line polymorphisms).2 3 This failure to find repro-
ducible HTE has supported the contrarian notion that 
true individual effects may be a ‘myth’, an overinterpreta-
tion of random noise.4
To distinguish between these two possibilities, Kalow et 
al5 have suggested that carefully designed series of N-of-1 
studies could be performed for those chronic conditions 
amenable to this design (ie, where the disease process 
is relatively stable over time, treatment effects are tran-
sient and outcomes vary and are observable over time). 
By estimating individual patient treatment effects and 
comparing the variation in effects between individuals to 
variation within individuals across different periods, it is 
possible to determine the non-random component of 
heterogeneity in individual treatment effects—even if 
one is unable to identify the variables that predict this 
variation (ie, even in the absence of group-level HTE, 
such as men vs women or old vs young).
A recent review summarised N-of-1 studies reported in 
the literature—including multiperson N-of-1 studies—but 
did not examine whether and how these studies provide 
information on person-level HTE. Therefore, our objec-
tives are (1) to summarise the conduct and reporting of 
assessments of variation in person-level treatment effects 
from N-of-1 studies and (2) to extract, reanalyse and 
report the results from the subset of studies that provided 
adequate data in their published reports to examine the 
extent of the evidence for person-level HTE (ie, partici-
pant-level outcomes or effects).6
MethODs
This review was conducted in accordance with the highest 
standards for conducting systematic reviews.7 8 We defined 
N-of-1 studies as crossover trials in which each patient 
receives two or more treatments in a predefined, often 
randomised, sequence.
Data sources and searches
We used two separate searches because N-of-1 studies 
can be indexed differently: (1) a search in Medline, 
Cochrane Central and EMBASE using terms related to 
repeated crossover studies (for publications indexed 
from inception to 17 August 2017) and (2) a Medline, 
Cochrane Central, EMBASE and Web of Science search 
using terms that are related to N-of-1 (for publications 
indexed from 2011 to 17 August 2017). For N-of-1 studies 
indexed before 2011, we used studies included in a prior 
published systematic review by Gabler et al.6 Our searches 
combined terms and Medical Subject Headings for 
N-of-1, single-subject, single-patient, randomised trials, 
crossover, multiperiod crossover and rotated or repeated 
period crossover (see online Supplementary appendix 
tables 1 and 2 for detailed search terms). The searches 
were not restricted by disease, condition, organ system or 
treatment.
study selection
We selected eligible multiperson N-of-1 studies to describe 
the frequency of reporting of individual outcomes and 
effects and of documented HTE in these studies. We 
required a minimum of two individual subjects per study 
for evaluation of HTE. We excluded studies that included 
non-pharmacological interventions, reviews, abstracts 
and protocols. We included studies with placebo or ‘no 
treatment’ interventions. Citations were double screened 
by reviewers using an open-source, online software 
Abstrackr (http:// abstrackr. cebm. brown. edu/). Full-text 
articles of potentially relevant studies were again double 
screened for eligibility.
Person-level outcomes were defined as outcomes 
for each person at each point in time when they were 
measured, reported in tables, text or graphs. Person-level 
treatment effect was defined as contrasts of outcomes 
in individuals on one treatment versus the comparator. 
Person-level HTE was defined as quantified variation in 
the person-level treatment effects, whereas HTE more 
broadly includes any type of subgroup analysis (eg, males 
vs females; older vs younger) as outlined in figure 1.
Data extraction and quality assessment
One of the four reviewers extracted data from each 
publication; a second reviewer verified all numerical 
information and basic descriptors of the study design 
and analysis. Operational definitions for extraction 
items were discussed in weekly project meetings and 
discrepancies between extractors were resolved by 
consensus with senior authors (DK, GR, EB). From each 
study, we extracted bibliographic information, details 
related to study design (number of patients enrolled, 
selection criteria, interventions evaluated, randomisa-
tion methods, outcomes assessed, follow-up duration), 
information on patient characteristics and person-level 
measurements of outcomes or estimates of person-level 
treatment effects (with corresponding measures of 
their uncertainty). When necessary, we extracted data 
by digitising the graphs and the values were estimated 
using Engauge Digitizer V.2.14 (http:// digitizer. source-
forge. net/). We assessed the methodological quality of 
each study based on predefined criteria, in accordance 
with the Agency for Healthcare Research and Quality 
suggested methods and the Cochrane risk of bias for 
clinical trials.9 10
We generated graphs showing the trajectory of response 
for each patient in each study and compared them against 
the published information. We also generated scatter-
plots of measurements over time for studies that did not 
present their data in graphical format to help us identify 
aberrant data points (eg, errors in data extraction). We 
verified potentially aberrant data points by re-examining 
the published data and made corrections, when needed.
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Data synthesis and analyses
We examined the degree to which studies reported 
person-level data. This was described using the following 
items for each reported outcome: (1) qualitative descrip-
tions of HTE (eg, ‘there were eight responders and four 
non-responders’); (2) details of person-level outcomes 
(ie, outcomes with each treatment within each period); 
(3) details of person-level treatment effect (ie, a point 
estimate of contrasts of outcomes in individuals on one 
treatment vs the comparator); (4) reporting of person-
level statistical effect estimate (eg, SD, exact p values or 
CIs for treatment effects within individuals); (5) descrip-
tion of statistical tests examining HTE (ie, tests evaluating 
the contrast of treatment effects between individuals or 
groups in the study) and (6) claims of HTE. Note that 
qualitative descriptions of HTE for item 1 would include 
any description that implied that treatment effects varied, 
whereas item six required a more definite study conclu-
sion (eg, ‘our results demonstrate significant variation 
across individuals in response to treatment X’), whether 
or not these conclusions were based on robust statistical 
tests.
statistical hte analysis of extracted study results
We performed statistical analysis testing for person-level 
HTE on all studies presenting person-level data. We used 
a consistent analytic strategy across studies, to the extent 
permitted by the reporting in published papers. Our 
strategy was different for studies that reported person-
level outcome measurements and those that reported 
estimates of person-level treatment effects with their 
sampling variances (or adequate information to approxi-
mately calculate these statistics).
For studies that only reported (or allowed the calculation 
of) estimates of person-level treatment effects, we obtained an 
average effect using a fixed effect inverse variance model 
and estimated the variance of the person-level treatment 
effects using DerSimonian and Laird method of moments 
estimator.11 12 In addition to a fixed effect model, we also 
obtained an average effect using a random-effects model. 
Finally, we tested the hypothesis that all person-level treat-
ment effects were equal using Cochran’s χ2 test and quan-
tified the proportion of observed variation due to ‘true’ 
person-level effect heterogeneity with the I2 statistic.13
For studies that reported person-level outcomes, we devel-
oped a linear model (for continuous outcomes) or gener-
alised linear model (for binary or count outcomes) using 
the outcome of interest as the response, the interven-
tion(s) as a covariate and indicator variables for different 
study participants.14 This model estimates a common 
treatment effect across participants. We also derived 
a similar model with treatment-by-participant interac-
tions. This model allows each patient to have a different 
effect. The statistical significance of person-level HTE 
was assessed by a likelihood ratio test comparing the two 
Figure 1 Schematic description of person-level outcomes (outcomes for each patient during each treatment period); person-
level effects (contrasts of the outcomes for each patient in one treatment condition vs another) and person-heterogeneity of 
treatment effects (between patient contrasts of effects).
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models. In addition to a fixed effect model, we also fit 
a hierarchical linear or generalised linear mixed model 
with a random intercept and a random slope (for the 
treatment effect) to estimate the average treatment effect 
across all patients (assuming person-level HTE). We tested 
the hypothesis that all person-level treatment effects were 
equal and quantified the proportion of observed varia-
tion due to ‘true’ person-level effect heterogeneity with 
the I2 statistic.13 For modelling within-patient variance, we 
used a common variance with an uncorrelated covariance 
structure, as was used in a prior N-of-1 study.14 Person-
level treatment effect was assumed to be equal across 
time periods. For the treatment effect, we used more than 
one random slope when more than two treatments were 
compared.
Patient and public involvement
Patients and the public were not involved in the design or 
analysis of this study.
results
The searches for repeated crossover studies identified 
11 891 citations and those for N-of-1 studies identified 
3819 citations (indexed from 2011 onwards). Of these, we 
retrieved 407 full-text articles for review plus 100 N-of-1 
trial articles (indexed before 2011) from an existing 
systematic review.5 On full-text screening, 62 studies (58 
multiperson N-of-1 studies and four repeated period 
crossover studies) met eligibility criteria (online supple-
mentary appendix tables 3) and are reported multiperson 
N-of-1 studies throughout the article. An outline of the 
search and study selection flow is provided in figure 2.
Description of studies
Table 1 summarises the 62 multiperson N-of-1 studies that 
were published between 1986 and 2017 reporting a total 
of 1974 patients. The most common clinical domains in 
the multiperson N-of-1 studies were neurology (16%), 
arthritis/rheumatology (10%) and psychiatry (9%). 
Most studies were described as ‘double blind’ but details 
about the methods for blinding were often unclear; simi-
larly studies often provided unclear information about 
the generation of the randomisation sequence and allo-
cation concealment (online supplementary appendix 
tables 4). Among the studies, 93% compared a pair 
of treatment strategies, 5% compared three strategies 
and 2% compared four strategies. Studies had between 
three and 16 treatment periods and obtained an average 
Figure 2 Study flow diagram represents the flow of eligible studies included in this review.
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of 1–42 outcome measurements per period. Across 
reported outcomes, 89% of the assessed outcomes were 
patient reported and 11% were investigator assessed.
reporting person-level outcomes, effects and hte
While most studies (92%) had some qualitative acknowl-
edgement that the treatment effects appeared to vary 
across individuals, formal reporting at the participant 
level was variable (table 2). Person-level outcomes under 
each treatment were reported in 52% of multiperson 
N-of-1 studies. Person-level treatment effects with quan-
titative data (comparing outcomes on each treatment) 
for each individual who completed the trial was available 
in 32%; and details on the statistical evaluation of these 
effects (as SD or exact pvalues or confidence intervals) 
were available in 13 (21%) multiperson N-of-1 studies. 
Only five (8%) studies described statistical tests exam-
ining any HTE. However, only two studies (3%) reported 
person-level HTE, whereas the others examined group-
level HTE using conventional subgroup analysis based on 
observable characteristics.
reanalysis of person-level data
Of the 62 studies, there were 36 studies that provided 
person-level data, either as outcomes in each treatment 
period or as person-level treatment effects (table 3). Of 
these, only 25 studies provided person-level data sufficient 
to support re-analysis: 14 studies provided person-level 
outcomes; 13 studies provided person-level treatment 
effects (two studies provided both). The remaining 11 
studies reported either medians or means without data 
on variance or did not provide sufficient information on 
completers, so they could not be reanalysed for treatment 
effect or HTE.
Of 13 studies (with 27 unique comparisons) that 
reported analysable person-level treatment effect data 
(table 3), 10 studies had a placebo comparator and three 
studies had an active comparator. The sample size ranged 
from 7 to 68; average crossover periods ranged from 6 
to 16 days and average outcome measures per period 
ranged from 1 to 21. The average treatment duration 
ranged from 14 to 336 days.
There were 14 studies (with 27 unique comparisons) 
that reported analysable person-level outcome data 
(table 3), including two studies also reporting person-
level treatment effects. Of these, 11 compared the inter-
vention with placebo and three studies compared two 
active interventions. The sample size ranged from 2 to 22; 
the average number of crossover periods ranged from 3 
to 10 and the average number of outcome measures per 
period ranged from 1 to 42. The average treatment dura-
tion ranged from 9 to 210 days.
Table 1 Evidence map of multiperson N-of-1 and repeated 
period crossover studies
Description
Multi-person N-of-1
studies (n=62)
Publication years 1979–2017
Subjects Total N (median, IQR)
  Enrolled 2153 (16, 9–42)
  Completed 1705 (12, 7–32)
Intervention and comparisons
  Head-to-head active drugs 10
  Placebo 47
  Active drug and placebo 1
Population
  Paediatric 12
  Adults 50
Major systems studied
  Arthritis/rheumatology 10
  Cardiovascular 3
  Gastrointestinal 7
  Hypertension 1
  Psychiatry 9
  Neurology 16
  Respiratory 9
  Miscellaneous* 7
Top 5 disease conditions
  ADHD 6
  Angina 3
  Chronic pain 5
  GORD 5
  Obstructive airway 6
  Osteoarthritis 6
*Sleep disorders, allergy, cancer, muscular, vascular (for 
multiperson N-of-1); pain, urology, GYN, Heme/Onc, allergy, 
dermatology, drug abuse, endocrine, lipids, nephrology, 
ophthalmology, respiratory (for repeated crossover studies).
ADHD, attention-deficit hyperactivity disorder; GORD, gastro-
oesophageal regurgitation disorder; n, number of participants.
Table 2 Survey of HTE assessment in multiperson N-of-1 
studies
HTE reporting
Multiperson N-of-1
studies (n=62)
Qualitative description 92%
Person-level outcomes 52%
Person-level treatment effects 32%
Statistical analysis of person-level 
effects (eg, p values)
21%
Any statistical test for HTE 8%*
Claims of heterogeneity 15%
*Only two studies reported person-level HTE, the remaining three 
studies reported group level effect.
HTE, heterogeneity of treatment effects.
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Table 3 Characteristics of studies reporting person-level data
Author, Year Disease
Number 
enrolled 
(analysed) Intervention Comparator
Cross-
over 
periods
Total 
intervention 
duration
Outcome 
measures 
per period
Studies with reanalysable person-level outcomes
Camfield, 
1996
Mental retardation with 
fragmented sleep
6 (6) Melatonin Placebo 7 10 weeks 14
Hinderer,
1990
Traumatic spinal cord 
injury
5 (5) Baclofen Placebo 3 9 weeks 2
Langer,
1993
Gastro-oesophageal 
reflux
2 (2) Cisapride Placebo 3 6 weeks 5
Lashner,
1990
Ulcerative colitis 7 (6) Nicotine Placebo 4 8 weeks 1
Maier,
1994
Chronic depression 10 (9) Sulpiride Placebo 4 28 weeks 42
Mandelcorn, 
2004
Brain injury 4 (4) Ondansetron Placebo 4 5 weeks 1
McQuay,
1994
Neuropathic pain 19 (19) Dextromethorphan Placebo 5 20 days 1
Miyazaki, 1995 Unstable angina 22 (22) Isosorbide dinitrate Isosorbide 
dinitrate: 
intermittent 
injection
3 9 days 6
Nathan,
2006
Paediatric brain tumour 12 (7) Ondansetron 
and metopimazine
Ondansetron 
and placebo
Unclear 189 days Unclear
Parodi,
1979
Unstable angina 12 (12) Verapamil Placebo 4 10 days Unclear
Parodi,
1986
Unstable angina 10 (10) Verapamil Propranolol, 
placebo
8 18 days Unclear
Tison,
2012
Levodopa-induced 
dyskinesia in patients 
with Parkinson’s disease
10 (10) Simvastatin Placebo 6 96 days 1
Studies with re-analyzable person-level treatment effects
Emmanuel,
2012
Chronic intestinal 
pseudo-obstruction
7 (4) Prucalopride Placebo 16 48 weeks 21
Haas,
2004
Chronic tension type and 
migraine headache
39 (16) Dextroamphetamine Equi-
stimulatory 
caffeine
8 20 days 20
Jaeschke,
1991
Fibromyalgia 22 (23) Amitriptyline Placebo 6 12 weeks 2
Johannessen,
1992
Dyspepsia 68 (46) Cimetidine Placebo 12 184 days 15
Lipka,
2017
Autoimmune myasthenia 
gravis
4 (4) Ephedrine Placebo 4 6 weeks 1
Mahon,
1996
Irreversible chronic 
airflow limitation
16 (14) Theophylline Placebo 8 73 days 1
March,
1994
Osteoarthritis 25 (15) Diclofenac Paracetamol 6 12 weeks 14
Patel,
1991
Non-reversible chronic 
airflow limitation
26 (18) Ipratropium bromide/
theophylline
/salbutamol
/beclomethasone
Placebo 6 6 weeks Unclear
Wallace,
1994
Attention deficit 
hyperactivity disorder
11 (7) Methylphenidate Placebo 14 14 days 1
Continued
7Raman G, et al. BMJ Open 2018;8:e017641. doi:10.1136/bmjopen-2017-017641
Open Access
reanalysis of studies reporting estimates of person-level 
treatment effects
Thirteen studies (including 27 comparisons, due to 
multiple outcomes in some studies) reported esti-
mates of person-level treatment effects sufficient 
to analyse (online supplementary appendix figures 
1–16 display graphs of the person-level treatment 
effect data). Average fixed effect estimates for each 
analysis are shown in table 4; random-effects esti-
mates were generally similar (online supplementary 
appendix tables 5). In 8 of the 13 studies (62%) and 
15 of the 27 total unique comparisons (56%), we 
found evidence of statistically significant HTE for at 
least one outcome (table 4). Generally, the magni-
tude in the variation of individual patient effects (as 
seen in the range) was very large compared with the 
average effects. Most studies (64%) showed person-
level effects that differed qualitatively from one 
another. Most of the variation in the observed indi-
vidual effects was attributable to ‘true’ (non-random) 
heterogeneity of person-level effects; 11 of 27 anal-
yses had I2 >80%.
Author, Year Disease
Number 
enrolled 
(analysed) Intervention Comparator
Cross-
over 
periods
Total 
intervention 
duration
Outcome 
measures 
per period
Woodfield,
2005
Skeletal muscle cramps 13 Quinine Placebo 6 14 weeks 2
Zucker,
2006
Fibromyalgia 58 Amitriptyline and 
placebo
Amitriptyline 
and fluoxetine 
combination
6 36 weeks 1
Study with both person-level data
Pereira,
1995
Atrial fibrillation/
deep venous thrombosis
7 Generic warfarin Coumadin 10 30 weeks 2
Joy,
2014
Statin-related myalgia 8 (7) Statin Placebo 6 33 weeks 3
Study with insufficiently reported person-level data
Person-level outcome data
Denburg,
1994
Systemic lupus 
erythematosus
10 Prednisone Placebo 6 30 weeks 1
Mitchel,
2015
Fatigue in advanced 
cancer
43 (33) Methylphenidate Placebo 6 18 days 6
Nikles,
2000
Osteoarthritis 14 Ibuprofen Paracetamol; 
placebo
6 12 weeks 14
Nikles,
2015
Dry mouth in advanced 
cancer
17 (4) Pilocarpine Placebo 6 18 days 6
Nikles,
2017
Acquired brain injury 53 (38) Nervous system 
stimulants
Placebo 6 18 days 6
Reitberg,
2002
Allergic rhinitis 36 Loratadine and 
chlorpheniramine
maleate
loratadine 
with placebo
8 32 days 4
Sheather-Reid,
1998
Chronic pain 8 Ibuprofen/codeine Placebo 6 12 weeks 14
Person-level treatment effects
Huber,
2007
Juvenile idiopathic 
arthritis
6 Amitriptyline Placebo 6 17 weeks 12
Privitera,
1994
Partial seizure 16 Dezinamide Placebo 6 35 weeks 6
Wegman,
2003
Osteoarthritis 13 Paracetamol Non-steroidal 
anti-
inflammatory 
drugs 
10 20 weeks 14
Wegman,
2005
Regular temazepam 
users
15 Temazepam Placebo 10 10 weeks 7
Table 3 Continued 
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reanalysis of studies reporting person-level outcome 
measurements
Because some of the 14 studies providing analysable 
outcome data had multiple outcomes (or multiple 
outcomes scales), there were a total of 27 comparisons with 
analysable data. (The online supplementary appendix 
figures 17–42 displays graphs of the person level outcome 
results.) Average fixed effect estimates for each anal-
ysis are shown in table 5; random effects estimates were 
generally similar (online supplementary appendix tables 
6). In eight of the 14 studies (57%) (17 of the 27 unique 
comparisons (63%)), there was statistically significant 
person-level HTE for at least one outcome. Again, the 
variation in individual effects was often large compared 
Table 4 Analysis results of studies reporting person-level treatment effects
Author, year Outcome Range of the scales (severity)
Main effect
Person-level heterogeneity of treatment 
effect (HTE)
Treatment effect (CI) P for HTE*
Treatment effect 
range I2 % (CI)
Emmanuel, 
2012
Bloating 0–4 (0=absent to 4=worst) −0.344 (−0.619 to −0.069) <0.001 −1.1 to −0.1 94 (88 to 97)
Pain 0–4 (0=absent to 4=worst) −0.440 (−0.771 to −0.110) <0.001 −0.2 to −1.4 96 (92 to 98)
Haas, 
2004
Chronic tension-type 
headache grade
0–3 (0=none to 3=severe) 0.772 (0.454 to 1.090) <0.001 0.04 to 1.9 84 (76 to 90)
Chronic migraine headache 
grade
0–3 (0=none to 3=severe) 0.542 (0.354 to 0.731) 0.067 0.2 to 0.83 37 (0 to 65)
Jaeschke, 
1991
Seven-point symptom scale 1–7 (higher scores represent better 
function)
0.427 (0.210 to 0.645) <0.001 −1.02 to 3.18 85 (79 to 89)
Tender point changes count Number of tender points 1.320 (0.404 to 2.236) <0.001 −4.33 to 9.0 72 (57 to 82)
Johannessen,
1992
Six-point symptom scale 0–6 (0=NR to 6=NR) 0.698 (0.466 to 0.931) <0.001 −1.67 to 3.17 66 (53 to 75)
Joy,
2014
VAS myalgia score 0–100 mm (0=none to 100=worst) 0.119 (−2.283 to 2.521) 0.996 −8.10 to 9.45 0 (0 to 68)
Symptom-specific VAS 0–100 mm (0=none to 100=worst) 1.937 (0.179 to 3.696) 0.797 −8.0 to 18.05 0 (0 to 68)
Pain severity score 0–10 (0=none to 10=worst) 0.086 (−0.215 to 0.387) 0.986 0.0 to 1.0 0 (0 to 68)
Pain interference score 0–10 (0=none to 10=worst) −0.016 (−0.095 to 0.064) 0.917 −0.02 to 0.75 0 (0 to 68)
Lipka,
2017
Quantitative myasthenia 
gravis score
0–3 (0=none to 3=severe) 1.006 (0.215 to 1.797) 0.803 0.67 to 1.67 0 (0 to 85)
Myasthenia gravis (MG) 
composite
0–50 2.891 (0.348 to 5.433) 0.177 −1.05 to 5.12 39 (0 to 80)
MG-activities of daily living 0–24 1.099 (−0.277 to 2.474) 0.047 0.03 to 3.0 62 (0 to 87)
VAS score 0–10 (0=none to 100=worst) 1.275 (−0.115 to 2.665) 0.190 −0.01 to 3.02 37 (0 to 78)
Mahon, 
1996
Dyspnoea in Likert Scale 1–7 (1=extremely short of breath to 
7=no shortness)
0.125 (−0.181 to 0.430) <0.001 −0.57 to 0.89 78 (58 to 88)
March, 
1994
Mean pain score on VAS 5 point Likert scale (0–100 mm) −7.093 (−11.939 to −2.248) <0.001 −33.8 to 4.1 98 (97 to 98)
Mean stiffness score on 
VAS
5 point Likert scale (0–100 mm) −5.992 (−11.280 to −0.704) <0.001 −36 to 10.7 97 (96 to 98)
Patel, 
1991†
Four-item symptom 
questionnaire (all compared 
with placebo)
1–7 (1=extremely short of breath to 
7=no shortness of breath)
0.340 (0.253 to 0.422) <0.001 −0.34 to 3.1 91 (87 to 94)
Four-item symptom 
questionnaire (use of 
ipratropium bromide)
0.675 (0.264 to 1.085) <0.001 −0.22 to 3.1 87 (78 to 92)
Four-item symptom 
questionnaire (use of 
salbutamol)
0.865 (0.042 to 1.687) <0.001 0.46 to 1.3 94 (NA)
Four-item symptom 
questionnaire (use of 
theophylline)
0.025 (−0.434 to 0.484) 0.172 −0.34 to 0.18 30 (0 to 93)
Pereira, 
1995
INR (diff) Target INR range of 2.0–3.0 0.027 (−0.155 to 0.209) 0.477 −0.28 to 0.37 0 (0 to 75)
Wallace, 
1994
Conners 15-item rating 
scale scores
0–3 (NR) 0.759 (0.341 to 1.178) 0.747 0.42 to 1.22 0 (0 to 79)
Woodfield,
2005
Changes in the number of 
cramps
Number—mean difference −18.823 (−28.527 to −9.120) <0.001 −77 to −2 92 (87 to 95)
Total days with cramps days −6.181 (−9.798 to −2.563) <0.001 −13 to −1 94 (90 to 96)
Zucker, 
2006
FIQ 0–100 (0=best to 100=worst) −5.019 (−8.784 to −1.254) 0.999 −32.0 to 0.98 0 (0 to 37)
*The significance of person-level HTE was assessed by Cochran’s Χ2-based test.
†One subject had beclomethasone.
FIQ, Fibromyalgia Impact Questionnaire; INR, international normalised ratio; NA, not applicable; NR, not reported; VAS, Visual Analogue Scale.
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Table 5 Studies reporting person-level outcomes
Author, year Outcome
Definition/range of the 
scales (severity)
Main effect
Person-level heterogeneity of treatment 
effect (HTE)
Fixed treatment effect
P for person 
treatment 
interaction*
Treatment effect 
range (lower range 
(CI)–upper range 
(CI)) I2 % (CI)
Camfield,
1996
Nights without 
awakening
Between 10:00 PM and 
7:00 AM per day
0.865 (0.215 to 1.516) 0.456 0.12 to 2.0 0 (0 to 79)
Hinderer,
1990
Anxiety Beck Inventory-A anxiety 
scale 0–3 (0=never, 
3=almost all the time)
0.000 (0.000 to 0.000) <0.001 −6.38 to 0.000 91 (81 to 95)
Joy,
2014
Myalgia score Visual Analogue Score 
for myalgia (0=none to 
100=worst)
3.3812 (−2.668 to 9.430) 0.565 −11.66 to 60.79 0 (0 to 68)
Langer,
1993
Vomiting Number of episodes −1.204 (−2.494 to 0.086) 0.136 −1.34 to 0.17 87 (NA)*
Lashner,
1990
Symptom score: 
abdominal pain
Symptom scores 0–100 
(0=best, 100=worst)
−3.615 (−16.982 to 9.751) 0.007 −35.0 to 15.0 37 (0 to 73)
Symptom score: bowel 
movements/day
−0.538 (−1.215 to 0.138) 0.001 −3.0 to 1.0 56.6 (0 to 81)
Symptom score: 
consistency of bowel 
movements
7.000 (−7.551 to 21.551) 0.013 −25.5 to 33.0 28 (0 to 69)
Symptom score: 
haematochezia
2.308 (−17.210 to 
21.826)
0.003 −38.0 to 47.5 47 (0 to 78)
Symptom score: 
general sense of well-
being
−6.538 (−25.352 to 
12.275)
0.008 −43.0 to 35.0 35 (0 to 73)
Maier, 
1994
SCL-90 subscales: 
depressed mood
Self-rating inventory to 
measure the effects of 
drug
−3.536 (−6.718 to −0.354) <0.001 −17.8 to 2.74 58 (12 to 80)
SCL-90 subscales: 
anxiety
−3.753 (−6.582 to −0.924) <0.001 −17.4 to 2.5 66 (30 to 83)
SCL-90 subscales: 
somatisation
−1.419 (−4.316 to 1.478) 0.869 −6.0 to 2.7 0 (0 to 65)
Mandelcorn,
2004
Self-assessment score 0–5 (0=worst, 5=best) −2.052 (−8.865 to 4.761) 0.05 −7.7 to 4.9 0 (0 to 85)
Lower extremity ataxia Fugl-Meyer: three point (0 
cannot be performed to 2 
can be fully performed)
12.494 (−3.155 to 28.142) 0.025 −6.42 to 36.76 35 (0 to 77)
Truncal ataxia AMTI force plate: NR
Berg Balance Scale 
0–56, with a higher 
score indicating a better 
performance
1.196 (−2.866 to 5.257) 0.690 −0.52 to 2.20 0 (0 to 85)
Upper extremity ataxia Purdue Pegboard Test: 
pegs inserted into the 
board with each hand 
in 30 s
Minnesota Placing Test: 
reach out, grasp, and 
place blocks in a specific 
order
−0.498 (−3.546 to 2.550) 0.382 −3.68 to 1.42 0 (0 to 85)
McQuay,
1994
VAS pain Intensity 0–100 (0=no pain, 
100=worst possible pain)
−1.094 (−5.572 to 3.383) 0.004 −8.0 to 10.1 0 (0 to 49)
VAS relief Intensity 0–100 (0=no relief, 
100=complete pain relief)
−3.913 (−11.729 to 3.903) 0.038 −28.4 to 5.15 0 (0 to 49)
Miyazaki,
1995
Incidence of angina Either ST segment 
elevation or depression 
at rest
0.496 (−0.206 to 1.199) 0.125 −16.19 to 17.11 0 (0 to 60)
Continued
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with the average effect. However, given the lower number 
of participants per study and periods per participant and 
also different analytic approach, estimates of I22 were 
much less precise in these studies.
DIsCussIOn
This review documents that multiperson N-of-1 studies 
rarely examine HTE. Only 8% of 62 multiperson N-of-1 
studies described statistical tests examining HTE, but these 
generally involved comparisons of treatment effects among 
groups of patients (eg, based on age or sex) rather than 
across individuals. Only two studies in the whole of the 
literature tested for person-level HTE.15 16 Nevertheless, 
analysable person-level results are sometimes reported in 
multiperson N-of-1 studies, as outcomes or as treatment 
effects, suitable for the analysis of person-level HTE. Our 
reanalyses of the totality of available data from these studies 
(n=25) suggested the presence of substantial non-random 
variation in treatment effects across individuals in most 
studies. This was evident when considering statistical tests 
for the variation of treatment effects among patients and 
also by qualitative assessment of the magnitude of effect 
variation. This represents the first broad empirical examina-
tion with reanalysis of person-level HTE across multiperson 
Author, year Outcome
Definition/range of the 
scales (severity)
Main effect
Person-level heterogeneity of treatment 
effect (HTE)
Fixed treatment effect
P for person 
treatment 
interaction*
Treatment effect 
range (lower range 
(CI)–upper range 
(CI)) I2 % (CI)
Nathan,
2006
Emetic episodes per 
day
Complete response 
(0 episodes/day), 
major response (1–2 
episodes/day) or failure 
(>2 episodes/day)
−0.095 (−0.514 to 0.325) 0.001 −16.5 to 2.08 59 (6 to 82)
Parodi, 
1979
Ischaemic attacks ST elevation or 
depression (details NR)
−1.544 (−1.838 to −1.251) 0.007 −16.21 to −0.34 48 (0 to 73)
Parodi, 
1986
Asymptomatic ST 
elevation (after 
verapamil)
0.1 mV of ST segment 
elevation measured 20 ms 
after the J point
−1.637 (−1.994  to −1.279) 0.110 −2.37 to −1.30 6 (0 to 65)
Asymptomatic ST 
depression (after 
verapamil)
More than 0.2 mV of 
ST segment depression 
measured 80 ms after the 
J point
−1.083 (−1.903 to −0.262) 0.401 −17.42 to −0.90 0 (0 to 62)
Symptomatic ST 
elevation (after 
verapamil)
−1.580 (−1.906 to −1.254) <0.001 −15.40 to −1.45 0 (0 to 62)
Symptomatic ST 
depression (after 
verapamil)
−0.990 (−1.411 to −0.569) 0.002 −2.53 to −0.52 6 (0 to 64)
Asymptomatic ST 
elevation (after 
propranolol)
0.100 (−0.086 to 0.286) 0.006 −0.77 to 1.38 62 (25 to 81)
Asymptomatic ST 
depression (after 
propranolol)
0.339 (−0.168 to 0.845) 0.964 −18.3 to 0.83 0 (0 to 62)
Symptomatic ST 
elevation (after 
propranolol)
−0.002 (−0.177 to 0.173) 0.063 −14.9 to 0.68 46 (0 to 74)
Symptomatic ST 
depression (after 
propranolol)
−0.374 (−0.709 to −0.039) 0.023 −17.1 to −0.73 4 (0 to 64)
Pereira,
1995
INR Target INR range of 
2.0–3.0
−0.126 (−0.312 to 0.060) 0.433 −0.42 to 0.16 0 (0 to 71)
Tison,
2012
Troublesome 
dyskinesia
7 points 
scale (1=extremely 
uncomfortable, 7=not at 
all uncomfortable)
0.167 (−0.449 to 0.783) 0.593 −0.67 to 1.83 0 (0 to 62)
*The significance of person-level HTE was assessed by a likelihood ratio test comparing the two models—model with common treatment effect 
and model with treatment-by-participant interactions.
INR, international normalised ratio; NR, not reported; SCL, Symptom Checklist.
Table 5 Continued 
11Raman G, et al. BMJ Open 2018;8:e017641. doi:10.1136/bmjopen-2017-017641
Open Access
N-of-1 studies, and it provides some general support for 
the a priori assumption of individual patient variation in 
treatment response that broadly motivates personalised 
medicine.
In contrast to parallel-group studies that establish effi-
cacy in a group of patients with a common condition, 
N-of-1 studies establish the effects of an intervention 
in an individual.17 In this respect, N-of-1 studies can be 
thought of as adjuncts to clinical care, where the goal 
is to select the right treatment for a particular patient, 
rather than as a research tool, where the goal is to create 
new generalisable knowledge.18 19 Indeed, the results 
of traditional N-of-1 studies may be generalisable only 
to the future treatment response of the patient in the 
trial, not to other patients. Nevertheless, using Bayesian 
meta-analytic techniques, Zucker et al showed how the 
average treatment effect at the population level can also 
be estimated by combining multiperson N-of-1 studies 
testing similar interventions in similar patients with the 
same outcome measures.14 Similar Bayesian methods 
have also been suggested for analysis of group-level 
HTE.20
Herein, we demonstrate yet a new application of N-of-1 
studies, to explore person-level HTE. This application has 
important research and clinical implications, even when 
the determinants of HTE remain unidentified. It is partic-
ularly of interest that there was apparent variation in the 
degree of person-level HTE found across conditions and 
treatments. Since the degree of variation across individ-
uals sets the upper bound for the amount of HTE that 
might be explainable by observable characteristics, such 
as clinical or genomic variables, searching for subgroup 
effects in the absence of person-level HTE is a futile exer-
cise.4 21 22
An interesting example of how person-level HTE can 
vary across different conditions comes from the study 
of Johannessen et al (figure 3).15 These investigators 
conducted N-of-1 patient studies comparing cimetidine 
to placebo for patients presenting with dyspeptic symp-
toms and reported person-level effects by subgroups of 
disease categories. Among 46 trial completers, cimetidine 
had a significant effect for most patients (57%), as it did at 
the aggregate level. However, not only was there substan-
tial person-level HTE, but person-level HTE varied across 
conditions, being much more pronounced in non-ulcer 
dyspepsia (I2=75%) compared with peptic ulcer disease 
(I2=35%) (figure 3)—despite the very similar overall 
effects seen in these two conditions.
Finding variation in person-level response in multi-
person N-of-1 studies identifies those conditions for which 
N-of-1 studies are likely to be clinically relevant. For condi-
tion-treatment combinations shown to have low person-
level HTE, single subject studies are highly unlikely to be 
clinically informative, and the average results from trials 
(ie, ‘one-size-fits-all’ effects) are more apt to be applicable 
to individuals.23 24 On the other hand, N-of-1 studies may 
be highly clinically informative for condition-treatments 
with a high degree of person-level HTE. These conditions 
would also be potentially higher yield for examining 
predictors of HTE (genomic or otherwise).
Our findings also have implications for clinical practice 
and formulary design. For conditions marked by high 
person-level HTE, even when trials show that one treat-
ment is better on average than others, having a variety of 
medication options would be useful to optimise outcomes 
across all patients, particularly for chronic conditions such 
as those studied here where empiric trials of alternative 
medications to find the best treatment for an individual 
might be feasible. For example, the study by March et al25 
shows that while patients with osteoarthritis on average 
had less pain and less stiffness with diclofenac, some 
patients had improved symptoms on paracetemol. This 
person-level HTE may not be detectable in conventional 
parallel-arm trials employing conventional subgroup 
analysis.21
While more studies combining N-of-1 studies are 
needed to understand the extent of person-level HTE, 
future studies need to apply greater methodological 
rigour to improve the state-of-the-science on evaluation 
of individual treatment effects.26 While the recently 
published Consolidated Standards of Reporting Trials 
Extension for N-of-1 trials may help improve reporting, 
a tabulation of all information (possibly electronically 
available) appears the most straightforward way to facil-
itate the clinical interpretation of these studies.27 Such 
reporting allows the inspection of trajectories over time 
and may reveal patterns that are not captured by regres-
sion models. Complete reporting would also facilitate the 
development and evaluation of methods for the analysis 
of single subject experiments, particularly its use to better 
understand the extent and importance of person-level 
HTE.
The limitations of this review reflect, to a large extent, 
the limitations of the data in primary studies. Many 
conditions are not amenable to the N-of-1 design (eg, 
because treatment effects are cumulative or because 
outcomes are observed only once). Further, even for 
conditions and treatment that are potentially amenable 
to this design, many important disease categories lacked 
published N-of-1 studies. We relied on published studies 
only and our analytic cohort may be an underestima-
tion of the true prevalence of these studies—particularly 
for N-of-1 studies, which may frequently be conducted 
without the intention of future publication.
In addition, our conclusions regarding the ubiquity 
of HTE in the data we reanalysed should be interpreted 
in the context of several important limitations. First, 
there were only a limited number of available studies 
that reported data sufficient to analyse, and therefore 
we present only a very partial picture of the full scope of 
interindividual variation in effects across clinical condi-
tions. Furthermore, among the studies that did have 
data, only fairly small number of patients were observed 
over a small number of treatment periods and we 
frequently had to rely on data summaries provided by 
the authors (eg, person-level treatment effects and their 
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sampling variance); these data limitations precluded 
the use of more complex models, for example, models 
that account for period effects or other effects of time 
on the outcome.3
Our review has demonstrated that HTE remains almost 
totally unexplored in multiperson N-of-1 studies, which 
are uniquely capable of exploring variations in individual 
(person-level) treatment effects. Our reanalysis of the 
Figure 3 Person-level variation across different disease conditions. This figure depicts the results of 46 different N-of-1 trials 
of cimetidine as reported by Johanessen et al.12 The effect of cimetidine versus placebo was measured in each subject across 
12 crossover periods over the span of 184 days. While cimetidine had a similar average effect regardless of the index condition, 
there was far greater consistency of effect in patients with peptic ulcer disease and much more variation in effect among 
patients with non-ulcer dyspepsia.
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data from these studies represents the first systematic 
attempt to obtain empirical support for the a priori argu-
ment that treatment effects vary across individual patients, 
an assumption which underpins all efforts to personalise 
treatment selection. In this sample, person-level HTE 
appears to be common and large enough to be clinically 
meaningful; the degree of person-level HTE appears to 
vary across conditions and outcomes. Thus, multiperson 
N-of-1 studies are an under-utilised tool to identify where 
person-level HTE may be substantial and where efforts to 
find molecular or clinical predictors of response hetero-
geneity should be focused. In such conditions, parallel 
arm studies might yield results that are over-generalised 
for patient level decision-making.
Author affiliations
1Center for Clinical Evidence Synthesis, Institute for Clinical Research and Health 
Policy Studies, Tufts Medical Center/Tufts University School of Medicine, Boston, 
MA, USA
2Center for Evidence Synthesis in Health, School of Public Health, Brown University, 
Providence, Rhode Island, USA
3Predictive Analytics and Comparative Effectiveness (PACE) Center, Institute for 
Clinical Research and Health Policy Studies, Tufts Medical Center/Tufts University 
School of Medicine, Boston, Massachusetts, USA
4Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research 
and Health Policy Studies, Tufts Medical Center/Tufts University School of Medicine, 
Boston, MA, USA
5VA Boston Healthcare System, Center for Healthcare Organization and 
Implementation Research (CHOIR), Boston, Massachusetts, USA
6National Pharmaceutical Council, Washington, District of Columbia, USA
7Department of Internal Medicine, University of California, Davis, San Francisco, 
California, USA
Acknowledgements We would like to acknowledge Issa Dahabreh, MD, MS, 
Assistant Professor of Health Services, Policy and Practice, Assistant Professor of 
Epidemiology, Brown University, for statistical advice. We would like to acknowledge 
Tatum Williamson, MS, Research Assistant, Predictive Analytics and Comparative 
Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts 
Medical Center, for assistance with updating literature.
Contributors GR and DMK made substantial contributions to the conception or 
design of the work; the acquisition, analysis or interpretation of data for the work; 
responsible for drafting the work or revising it critically for important intellectual 
content and have made an agreement to be accountable for all aspects of the 
work in ensuring that questions related to the accuracy or integrity of any part of 
the work are appropriately investigated and resolved. All authors have given final 
approval of the version to be published.
Funding This work was supported by the National Pharmaceutical Council. 
Additional support was provided by the Patient-Centered Outcomes Research 
Institute (PCORI) Award (Predictive Analytics Resource Center (SA.Tufts.PARC.
OCSO.2018.01.25) and the National Institutes of Health (3UL1TR001079-04S1). 
Disclaimer All statements in this report, including its findings and conclusions, 
are solely those of the authors and do not necessarily represent the views of the 
Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors or 
Methodology Committee. 
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerenCes
 1. Wallach JD, Sullivan PG, Trepanowski JF, et al. Sex based subgroup 
differences in randomized controlled trials: empirical evidence from 
Cochrane meta-analyses. BMJ 2016;355:i5826.
 2. Hertz DL, McLeod HL. Use of pharmacogenetics for predicting 
cancer prognosis and treatment exposure, response and toxicity. J 
Hum Genet 2013;58:346–52.
 3. Kitsios GD, Kent DM. Personalised medicine: not just in our genes. 
BMJ 2012;344:e2161.
 4. Senn S. Individual response to treatment: is it a valid assumption? 
BMJ 2004;329:966–8.
 5. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- 
and intra-individual variations can substitute for twin studies in drug 
research. Pharmacogenetics 1998;8:283–9.
 6. Gabler NB, Duan N, Vohra S, et al. N-of-1 trials in the medical 
literature: a systematic review. Med Care 2011;49:761–8.
 7. Institute of Medicine (US) Committee on Standards for Systematic 
Reviews of Comparative Effectiveness Research. Finding What 
Works in Health Care: Standards for Systematic Reviews, 2011.
 8. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. Ann 
Intern Med 2009;151:264.
 9. AHRQ. Methods guide for effectiveness and comparative 
effectiveness review. AHRQ Publication No 10(11)-EHC063-EF 
Chapters 2011. http:// effectivehealthcare. ahrq. gov/
 10. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane 
Collaboration's tool for assessing risk of bias in randomised trials. 
BMJ 2011;343:d5928.
 11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin 
Trials 1986;7:177–88.
 12. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models 
in meta-analysis: model properties and an empirical comparison of 
differences in results. Br J Math Stat Psychol 2009;62(Pt 1):97–128.
 13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-
analysis. Stat Med 2002;21:1539–58.
 14. Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be 
combined to give population comparative treatment effect estimates: 
methodologic considerations. J Clin Epidemiol 2010;63:1312–23.
 15. Johannessen T, Petersen H, Kristensen P, et al. Cimetidine on-
demand in dyspepsia. Experience with randomized controlled single-
subject trials. Scand J Gastroenterol 1992;27:189–95.
 16. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and 
generic warfarin interchangeable? Multiple n-of-1 randomized, 
crossover trials. Ann Pharmacother 2005;39:1188–93.
 17. Guyatt GH, Heyting A, Jaeschke R, et al. N of 1 randomized trials for 
investigating new drugs. Control Clin Trials 1990;11:88–100.
 18. Guyatt G, Sackett D, Taylor DW, et al. Determining optimal 
therapy – randomized trials in individual patients. N Engl J Med 
1986;314:889–92.
 19. Guyatt G, Sackett D, Adachi J, et al. A clinician's guide for 
conducting randomized trials in individual patients. CMAJ 
1988;139:497–503.
 20. Henderson NC, Louis TA, Wang C, et al. Bayesian analysis of 
heterogeneous treatment effects for patient-centered outcomes 
research. Health Serv Outcomes Res Methodol 2016;16:213–33.
 21. Dahabreh IJ, Hayward R, Kent DM. Using group data to treat 
individuals: understanding heterogeneous treatment effects in 
the age of precision medicine and patient-centred evidence. Int J 
Epidemiol 2016;45:dyw125.
 22. Senn S, Rolfe K, Julious SA. Investigating variability in patient 
response to treatment--a case study from a replicate cross-over 
study. Stat Methods Med Res 2011;20:657–66.
 23. Simon G. Choosing a first-line antidepressant: equal on average 
does not mean equal for everyone. JAMA 2001;286:3003–4.
 24. Simon GE, Psaty BM, Hrachovec JB, et al. Principles for evidence-
based drug formulary policy. J Gen Intern Med 2005;20:964–8.
 25. March L, Irwig L, Schwarz J, et al. n of 1 trials comparing a non-
steroidal anti-inflammatory drug with paracetamol in osteoarthritis. 
BMJ 1994;309:1041–4.
 26. DEcIDE Methods Center N-of-1 Guidance Panel. In: Kravitz RL, Duan 
N, eds. Design and implementation of N-of-1 trials: a user's guide. 
AHRQ Publication No. 13(14)-EHC122-EF. Rockville, MD: Agency for 
Healthcare Research and Quality, 2014.
 27. Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for 
reporting N-of-1 trials (CENT) 2015 statement. BMJ 2015;350:h1738.
